IMPACT OF COMBINED-MODALITY THERAPY ON THE TREATMENT OF ADENOCARCINOMA OF THE COLON

被引:5
|
作者
POSNER, MR
BLEDAY, R
HUBERMAN, M
JESSUP, JM
BUSSE, P
STEELE, G
机构
[1] Department of Medicine, Division of Hematology-Oncology, Harvard Medical School, Boston, Massachusetts
[2] Department of Surgery, New England Deaconess Hospital, Harvard Medical School, Boston, Massachusetts
[3] Joint Center for Radiation Therapy, Harvard Medical School, Boston, Massachusetts
来源
SEMINARS IN SURGICAL ONCOLOGY | 1993年 / 9卷 / 01期
关键词
COLONIC NEOPLASMS; ADJUVANT THERAPY; PROGNOSIS; CHEMOTHERAPY;
D O I
10.1002/ssu.2980090107
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An emphasis on careful surgical staging of adenocarcinoma of the colon has improved the predictive value of tumor staging systems. As a result of improved staging and carefully conducted randomized clinical trials, adjuvant therapy of locally advanced colon cancer, based on 5-fluorouracil chemotherapy, has been proven to substantially reduce recurrence rates and significantly increase overall survival for selected patients. Improved treatments and schedules are currently being studied in randomized trials and may increase the efficacy of this adjuvant therapy. Radiation therapy has not as yet been integrated into the adjuvant treatment of colon carcinoma. The application of a combined approach of surgery and chemotherapy in selected patients with liver metastases may also improve cure rates and long-term survival. The developing understanding of molecular determinants for the biological behavior of these cancers will increase the opportunities to identify, on the one hand, those patients who will benefit from specific therapies, and, on the other hand, new therapeutic strategies and treatments. (C) 1993 Wiley-Liss, Inc.
引用
收藏
页码:33 / 38
页数:6
相关论文
共 50 条
  • [21] THE PROMISE OF BIOCHEMICAL MODULATION IN COMBINED-MODALITY THERAPY
    VOKES, EE
    SEMINARS IN ONCOLOGY, 1994, 21 (06) : 29 - 33
  • [22] CHEMOTHERAPY AND COMBINED-MODALITY THERAPY FOR ESOPHAGEAL CANCER
    KELSEN, DP
    ILSON, DH
    CHEST, 1995, 107 (06) : S224 - S232
  • [23] Targeted radionuclide therapy in combined-modality regimens
    Gill, Martin R.
    Falzone, Nadia
    Du, Yong
    Vallis, Katherine A.
    LANCET ONCOLOGY, 2017, 18 (07): : E414 - E423
  • [24] Combined-modality therapy in paranasal sinus cancer
    Papadimitrakopoulou, VA
    Hong, WK
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1999, 5 (04): : 208 - 210
  • [25] RESPONSE WITH COMBINED-MODALITY TREATMENT IN CHILDHOOD RHABDOMYOSARCOMA
    RAJE, NS
    RAO, SR
    VAIDYA, SJ
    SHAH, RV
    NAIR, CN
    PAI, SK
    KURKURE, PA
    PANDE, SC
    DESAI, PB
    ADVANI, SH
    JOURNAL OF SURGICAL ONCOLOGY, 1993, 54 (04) : 243 - 245
  • [26] Combined-modality neoadjuvant therapy for rectal cancer
    O'Connell, MJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5450 - 5451
  • [27] Combined-modality treatment of leptomeningeal gliomatosis - Comments
    Loeffler, JS
    Chang, S
    Berger, MS
    Sawaya, R
    Groves, MD
    NEUROSURGERY, 2003, 52 (02) : 330 - 330
  • [28] PERIOPERATIVE COMBINED-MODALITY TREATMENT FOR CANCER OF THE ESOPHAGUS
    PORSCHEN, R
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 1993, 31 (11): : 680 - 685
  • [29] Retroperitoneal sarcomas: Combined-modality treatment approaches
    Raut, Chandrajit P.
    Pisters, Peter W. T.
    JOURNAL OF SURGICAL ONCOLOGY, 2006, 94 (01) : 81 - 87
  • [30] Milestones in the Use of Combined-Modality Radiation Therapy and Chemotherapy
    Lawrence, Theodore S.
    Haffty, Bruce G.
    Harris, Jay R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (12) : 1173 - +